Xcenda GmbH
Industry / private company
Location:
Hannover,
Germany (DE)
Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracereoral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care (2022)
Huttner H, Gerner S, Kuramatsu J, Connolly SJ, Beyer-Westendorf J, Demchuk AM, Middeldorp S, et al.
Journal article
ANDEXANET ALFA VERSUS USUAL CARE IN PATIENTS WITH DOAC ASSOCIATED INTRACEREBRAL HEMORRHAGE: A PROPENSITY-SCORE BASED HISTORICAL COMPARISON OF PATIENTS FROM ANNEXA4 AND RETRACEII (2020)
Huttner H, Gerner S, Connolly S, Middeldorp S, Milling T, Beyer-Westendorf J, Altevers J, et al.
Conference contribution